Introduction
Much maligned in this era of novel targets, 'conventional chemotherapeutic agents' have cured millions of cancers, and prolonged the lives of countless patients. While the 'novelist' argues that conventional agents have limited potential, the 'conventionalist' counters that these agents are proven cytotoxic compounds that fail only because mechanisms of resistance impede their activity. Taking the latter argument one step further, it follows that if the mechanisms of resistance can be overcome, the spectrum of activity of traditional agents will be extended.
A 'novelist' arguing that conventional agents have limited potential could cite countless examples in support of their thesis. Consider, for example, a strategy discussed below: restoration of the wild-type (wt) p53 function to cells harboring a mutant p53 or a null phenotype. Although it is often stated that wt p53 protein is required to induce apoptosis following exposure to a variety of chemotherapeutic agents, incontrovertible evidence indicates that this represents a simplified exaggeration. Consider the data from the NCI Anticancer Drug Screen (Weinstein et al., 1999) . Among 55 of the most extensively studied cell lines, 37 harbor a mutant p53, while 18 contain a wt p53. The only difference conferred by p53 status is the drug concentration required to kill cells harboring mutant p53 compared to those with a wt p53. For many drugs higher concentrations are required to kill cells harboring mutant p53; but once achieved, cell death occurs. All that one can expect to accomplish by restoring wt p53 to a cell harboring a mutant gene is drug sensitivity that approaches that of cells containing a wt gene. Unfortunately, clinically, the majority of tumors with a wt p53 do not respond to chemotherapy because other resistance mechanisms exist.
A similar case can be made for any drug resistance mechanism. For example, effective inhibition of Pglycoprotein (Pgp)-mediated efflux will increase intracellular drug concentrations in Pgp-expressing cells to levels comparable to those found in cells that do not express Pgp. But the harsh reality is that many cancers that do not express Pgp also do not respond to therapy. Likewise, knocking out an antiapoptotic protein will not cure all cancers.
We concede that these approaches like many others have only limited potential. Does this mean they should not be pursued? We would emphatically argue that the answer is no. Unless dozens of magic bullets are identified in our lifetime, the therapy of cancer will continue to be incremental in nature. We already recognize that even a drug like Gleevec (STI 571) is another building block in the therapy of cancer. Its initial promising results in CML (chronic myelogenous leukemia) and GIST (gastrointestinal stromal tumors) will be further enhanced when it is combined with other existing and yet to be discovered therapies.
Thus, this review will concentrate on therapies with real, but admittedly limited benefits. We will focus on strategies that have been tested or proposed to reverse drug resistance. While we will address various mechanisms of resistance and introduce our biases, we will not rigorously examine the validity of putative mechanisms of drug resistance. We will assume that their validity has been established, albeit with varying certainty. To be sure, time will demonstrate that many of the mechanisms presumed to confer drug resistance are either of no or limited importance in clinical oncology. However, regardless of the clinical significance of an individual mechanism of tolerance, much can be learned from examining the strategies used to overcome drug resistance. For clarity, each mechanism of resistance will be examined independently, although this will incur limited overlap in the presentation. In addition where appropriate, the strategies utilized will be discussed in detail, with their strengths and weaknesses outlined.
Targeting BCL-2, BCL-X L and other proteins involved in apoptosis as a means to modulate drug resistance Not long ago, as the apoptosis story unfolded, proapoptosis bax struggled with antiapoptosis Bcl-2 in the battle of the rheostat (Korsmeyer et al., 1993) . Then things got complicated (Adams and Cory, 1998; Reed, 2000) . Today, we recognize that apoptosis or programmed cell death is the outcome of a complex interplay of pro-and antiapoptosis molecules. Prosurvival Bcl-2 and its helpers compete with bax and other proapoptosis proteins to regulate the discharge of proteins and cytochrome c from mitochondria, which will in turn activate 'initiator' caspases. Activation of the latter leads to a cascade whose flow is regulated by a family of inhibitors of apoptosis (IAPs) and their antagonists. While it is often stated that chemotherapeutic agents induce apoptosis, it is clear that this is neither true for all cells, nor for all drugs. However, it does seem to be true for cancer cells arising from normal cells that under normal circumstances undergo apoptosis, such as lymphoid and germ cells. For these cells, strategies that promote apoptosis appear promising as a means to enhance chemotherapy efficacy.
As the process of apoptosis is so complex, it provides several potential sites for therapeutic intervention. Although the complexity has built in a system of checks and balances, it must be recognized that: (1) not all components are present or active in all cells; and (2) the balance that exists between pro-and antiapoptosis forces may be altered by affecting a single component. For example, overexpression of Bcl-2, commonly found as the single anomaly in follicular lymphomas, appears to be sufficient to tip the balance in this disease. Thus, from a therapeutic standpoint, what is important is the recognition that the process of apoptosis is intricately and finely balanced. The goal is to perturb this balance. How this is accomplished is not important, as long as the outcome is enhanced apoptosis. Several targets and approaches are being pursued, including the suppression of proteins inhibiting apoptosis using antisense oligonucleotides (ASOs), and small molecules targeted at proteins that modulate apoptosis.
Suppression of proteins involved in apoptosis can be achieved using ASOs, and plasmid or viral vectors. Antisense strategies attempt to block the expression of specific genes. The strategy farthest along in development employs antisense or reverse complimentary oligonucleotides composed of short sequences of single-stranded DNA complementary to mRNA (Olie and Zangemeister-Wittke, 2001; Tamm et al., 2001) . ASOs hybridize by Watson-Crick base pairing to messenger RNA leading to the formation of a heteroduplex of DNA and mRNA that engages RNAse H. The endonuclease, RNAse H, cleaves and thus destroys the mRNA strand of the heteroduplex, releasing the ASO intact to hybridize to another mRNA. Alternately, steric hindrance by the ASO prevents proper association of the mRNA with ribosomes, thus inhibiting protein synthesis. The outcome of either of these effects is a reduction of the protein whose mRNA was the target of the ASO. ASOs of 16-24 bases in length are considered optimal; shorter or longer oligonucleotides are associated with higher nonspecific hybridization. Selection of target areas must take into consideration the tertiary structure of the mRNA, since this will determine accessibility. The first six codons of an mRNA identified by the AUG start site are usually accessible and are often chosen as the starting point for the development of ASOs. However, target sequences are often identified empirically by screening oligonucleotides using mRNA levels as the endpoint. As DNAse present in cell culture medium and blood easily degrades short oligonucleotides, phosphorothioates in which a sulfur atom substitutes one of the phosphodiester oxygens have been developed. Phosphorothioates are nuclease resistant, can enter cells and hybridize the target mRNA effectively. Disadvantages to the use of ASOs include the problem of degradation, which has been largely resolved with the use of phosphorothioates, as well as nonspecific binding to proteins and antisense unrelated effects. Furthermore, high concentrations of oligonucleotides are required to inhibit gene expression.
While both ASOs and vectors encoding antisense sequences have been shown in vitro to reduce the levels of the target mRNA, it is very difficult to achieve complete disappearance of the message of interest, and in turn disappearance of protein and abrogation of function, where the latter can be measured (Chan et al., 2000) . Furthermore, the inhibition must be sustained for a sufficiently long period of time to allow for the protein to be degraded. If the protein targeted by the antisense strategy has a short half-life, then this is likely to be achieved without significant difficulty. However, if the half-life of the protein is long, complete disappearance is less likely to be achieved.
ASOs have been used to target oncogenes (Barton and Lemoine, 1995; Kimura et al., 1995) TGFb (Fakhrai et al., 1996) and the glucose transporter (Chan et al., 1999) among others. A strategy that has received intense interest is one that targets Bcl-2. While the importance of Bcl-2 has been admittedly overstated, the evidence suggests that at least in some models, overexpression of Bcl-2 is associated with resistance to chemotherapy. In these cells, it is thought that by preventing apoptosis, Bcl-2 essentially converts cytotoxic agents into cytostatic agents, allowing the cell to repair damage. The rationale for developing ASOs envisions downregulation of Bcl-2 enhancing the sensitivity of cancer cells to chemotherapeutic agents.
ASOs have been tested clinically with interesting, albeit inconclusive results. ASOs targeting Bcl-2 have been shown to cause tumor regressions as single agents (Klasa et al., 2002) . Demonstration of activity in combination with conventional cytotoxic agents awaits ongoing trials. This strategy is being pursued in hematologic malignancies, where it is most likely to succeed, as well as in solid tumors, where the significance of modulating apoptosis is less clear. As the clinical data demonstrating a correlation between chemoresistance and Bcl-2 levels are more persuasive than that showing Bcl-2 as a mechanism of acquired resistance, one would predict that this strategy would be most successful if employed in the initial therapy of tumors, rather than in drug-refractory malignancies. A similar rationale supports the development of ASOs targeting the functional and structural homolog of Bcl-2, Bcl-X L (Heere-Ress et al., 2002) . It remains to be established if a strategy that targets both Bcl-2 or Bcl-X L using either individual or bispecific ASOs will be more effective (Miyake et al., 2000; ZangemeisterWittke et al., 2000) .
In contrast to the antisense strategy that seeks to reduce expression levels, an alternate approach has attempted to suppress the activity of antiapoptotic Bcl-2 family members. To accomplish this, investigators have sought to exploit the BH3 domain, an amphipathic ahelix about 16 amino acids in length, found in nearly all Bcl-2 family members. When inserted into a hydrophobic crevice on the surface of antiapoptotic family members such as Bcl-2 and Bcl-X L , the BH3 domain impairs their function, and promotes apoptosis. A Bcl-2 family subgroup designated the BH3-only proteins, possesses only the BH3 domain. These BH3-only proteins are often linked to pathways mediating cell death and function as transdominant inhibitors of antiapoptotic members. Peptides homologous to the BH3 domain have been demonstrated to induce apoptosis, leading to efforts to identify molecules that mimic BH3 as inducers of apoptosis. Although the search for small molecules to inhibit Bcl-2 and Bcl-X L proved difficult, recent studies have succeeded in identifying lead candidates. In one study, investigators screened over 16 000 compounds by monitoring the displacement of fluorescently labelled BakBH3 peptide from Bcl-X L . Using this strategy, they identified two classes of compounds designated BH3Is that disrupt the BH3-Bcl-X L interaction (Degterev et al., 2001) . In a second study, antimycin A was serendipitously shown to mimic BakBH3 peptide in binding to Bcl-X L and Bcl-2 (Tzung et al., 2001) . As these effects were achieved with micromolar concentrations of these drugs, it is unlikely that these lead compounds will emerge as drug candidates. However, it is likely that structure-based rational design will lead to the identification of molecules with higher affinities. Use of such compounds seems especially feasible in an approach to modulate apoptosis in combination chemotherapy regimens, and not as single agents.
A final approach to enhance apoptosis targets the IAPs. The IAPs are a family of evolutionarily conserved proteins that suppress apoptosis by binding and inhibiting caspases. Current efforts draw their inspiration from the SMAC (DIABLO) protein, which binds and inhibits several members of the IAP family promoting apoptosis. Four to seven amino-acid peptides from the N-terminus of SMAC (DIABLO) are sufficient to block caspase binding and inhibition by IAPs (Chai et al., 2000) . Using these peptides as a starting point, small molecule mimetics have been identified and are being developed to enhance apoptosis. As peptides are small and usually very stable chemically, they are easy to work with and to derivatize, making them attractive reagents. The existence of naturally occurring peptides that have been used as chemotherapeutic agents suggests that such reagents can be effective (Aina et al., 2002; Hamel, 2002) .
Modulating methylation status to regulate drug sensitivity
Numerous studies have documented methylation of promoters in human cancer. Included among these are the promoters of genes considered crucial to oncogenesis, such as the tumor suppressors, Rb and p16. However, the significance of this remains unclear. Contributing to the uncertainty is the lack of evidence that re-expression of these genes significantly affects
Strategies for reversing drug resistance T Fojo and S Bates tumor growth. While in some models re-expression of putative tumor suppressors has resulted in some growth inhibition, it is argued that this will not be sufficient to impact significantly the growth of tumors that have acquired multiple other mutations (Bender et al., 1998) . Thus some investigators have focused their efforts on modulating the expression of genes that affect drug sensitivity as a means to exploit the activity of demethylating agents (Plumb et al., 2000) . 5-azacytidine and 2 0 -deoxy-5-azacytidine (DAC, decitabine) have been used as demethylating agents in vitro, and clinically in the treatment of acute myelogenous leukemia and myelodysplatic syndromes (Glover et al., 1987; Momparler et al., 1997) . DAC appears to be more effective. With either agent, expression of the genes of interest usually begins after several days of treatment, with peak expression occurring a few days later.
Modulation of hMLH1 represents an example of attempts to enhance drug sensitivity using a demethylating agent. The catalyst for these studies has been the knowledge that a majority of sporadic tumors with loss of mismatch repair (MMR) are deficient in MLH1 in association with hypermethylation of the promoter region. Clinically, several studies have reported correlations between hMLH1 expression and drug resistance or prior therapy (Strathdee et al., 1999; Mackay et al., 2000) . In vitro, loss of MMR proficiency results in resistance to DNA-damaging agents including cisplatin and doxorubicin, suggesting that for some drugs, MMR proteins may provide the link between DNA damage and the activation of apoptosis (Aebi et al., 1997; Brown et al., 1997; Plumb et al., 2000) . Re-expression of MLH1 either by gene transfer or following treatment with 5-azacytidine or 2 0 -deoxy-5-azacytidine (DAC, decitabine) enhances sensitivity to cisplatin, doxorubicin, epirubicin and temozolomide (Durant et al., 1999; Strathdee et al., 1999; Plumb et al., 2000) . In vivo experiments have shown that nontoxic doses of DAC can induce MLH1 expression and enhance drug sensitivity (Plumb et al., 2000) .
Some studies suggest that total demethylation of gene promoters is not needed for re-expression, because transcriptional repression depends on CpG methylation density rather than complete hypomethylation (Hsieh, 1994) . However, in one in vivo study that examined both DNA methylation and gene expression in xenografts as well as global DNA methylation in peripheral mononuclear cells, doses of DAC that did not induce MLH1 expression in vivo had no effect on global DNA methylation, suggesting a dose-response to DAC both in terms of MLH1 expression and global DNA methylation (Plumb et al., 2000) .
While many studies have focused on demethylation as the endpoint, success will most likely be achieved if this strategy is used to modulate gene expression in combination with other modalities such as chemotherapy. The key to a strategy that combines agents that modulate gene expression with conventional cytotoxics will be the drug schedule and the duration of treatment. For example, a clinical study that evaluated the combination of DAC and cisplatin administered DAC as a 30-min infusion on 3 successive days followed by cisplatin on day 4. Data from subsequent studies indicate that the duration of pre-exposure to DAC was probably insufficient (Plumb et al., 2000) . It is likely that clinical efficacy will be achieved only if a lead-in period of DAC administration longer than 3 days is used, possibly at higher doses.
Depletion of glutathione to modulate drug resistance
Glutathione (GSH) is a ubiquitous cysteine-containing tripeptide that is synthesized in two steps from aminoacid precursors. The first step involves the joining of glutamic acid and cysteine and is catalysed by gglutamyl cysteine synthase (g-GCS), the rate-limiting enzyme in GSH synthesis. The second step involves the addition of glycine to form GSH. As the predominant cellular thiol, intracellular GSH concentrations can exceed 10 mm. Owing to its reactivity and high intracellular concentrations, GSH has been implicated in resistance to several chemotherapeutic agents. Included among these are platinum-containing compounds, alkylating agents such as melphalan, anthracyclines including doxorubicin, as well as arsenic.
The inability to find a single, predominant resistance mechanism for platinum compounds has led to the consensus that resistance to platinum is multifactorial. Included among the mechanisms implicated in resistance to platinum compounds is an increased level of GSH. According to this model, cellular thiols inactivate platinum-containing chemotherapeutics before they reach their target, and enhance DNA repair by providing a suitable reducing environment. In some models, including cisplatin-selected human ovarian carcinoma cells, cisplatin resistance is associated with a proportional increase in cellular GSH concentrations, coinciding with a progressive increase in the expression of g-GCS (Yao et al., 1995) .
GSH has also been implicated as a contributor to anthracycline (adriamycin, daunomycin) resistance (Lai et al., 1991) . Early studies demonstrating that GSH was important in anthracycline metabolism provided one explanation for how GSH might contribute to resistance (Kramer et al., 1988) . Subsequent investigations demonstrating drug efflux by MRP1 added another potential role for GSH. Enhanced drug efflux mediated by MRP1 and MDR-1 is included among the multiple mechanisms that confer anthracycline resistance. Depletion of intracellular GSH increases the sensitivity of MRP1-expressing but not of MDR-1-expressing cells, suggesting a requirement for GSH in MRP-1-mediated anthracycline resistance (Benderra et al., 2000) .
The requirement for GSH to achieve optimal MRP1 drug transport might also explain recent observations with arsenic trioxide. Previous studies have shown increased efflux and reduced cellular accumulation of arsenic in MRP1-expressing cells (Vernhet et al., 2000) . Initial studies demonstrated that the basal level of GSH predicted response to arsenic trioxide treatment (Dai et al., 1999) . More recent studies have shown that growth inhibition by arsenic trioxide in multiple myeloma cells is facilitated by GSH depletion (Gartenhaus et al., 2002) . While caspase activation was noted in the latter study, suggesting apoptosis may have been enhanced, the importance of drug efflux may have been overlooked. Numerous studies have shown that MRP1 mediates the efflux of arsenical compounds. The contribution of GSH to this process was initially inferred but more recently has been clearly demonstrated in transfection studies (Lorico et al., 2002) . In the latter, retroviral vector-mediated overexpression of MRP1 and the heavy and light subunits of g-GCS resulted in higher GSH levels and a greater level of resistance to sodium arsenite compared to overexpression of either MRP1 or the g-GCS heavy subunit alone. These results demonstrate that MRP1 can confer resistance to arsenical compounds, and that GSH is an important cofactor in this process. They further suggest that reduction of GSH levels might enhance sensitivity to arsenical compounds by impairing its efflux.
Given the evidence suggesting that increased GSH levels confer resistance to several chemotherapeutic agents, three strategies designed to deplete intracellular GSH levels have been pursued. The first uses lbuthionine-(S,R)-sulfoxime (BSO), a potent and specific inhibitor of g-GCS, the rate-limiting step in the synthesis of GSH (Griffith and Meister, 1979) . BSO has been shown both in vitro and in vivo to reduce intracellular GSH levels, increasing sensitivity to platinum-containing compounds, alkylating agents, anthracyclines and arsenic trioxide (Lai et al., 1991; Bailey, 1998; Gartenhaus et al., 2002) . Trials in humans have shown that administration of BSO depletes intracellular GSH levels in circulating white blood cells by as much as 60-80% (Yao et al., 1993; Bailey et al., 1994) . Although in vitro studies suggest that drug sensitivity increases with increasing GSH depletion, even partial depletion can enhance sensitivity (Lai et al., 1991) . What remains to be determined is the extent to which this depletion enhances tumor cell sensitivity without augmenting toxicity to normal cells. Ongoing trials should provide definitive answers to these questions.
A second strategy that has not been tested clinically involves the use of a hammerhead ribozyme against g-GCS mRNA to downregulate its levels specifically (Nagata et al., 2001) . In vitro this strategy has been shown to enhance sensitivity to a variety of chemotherapeutic agents, most probably by affecting target repair as well as modulating MRP-mediated drug efflux.
A third strategy has been to target cJun expression to reduce GSH levels. As noted above, previous studies have shown increased levels of g-GCS and GSH in cisplatin-resistant cell lines. These increases were associated with a stable increase of c-jun expression and of cJun binding to AP-1 elements in extracts of nuclear protein (Godwin et al., 1992; Yao et al., 1995) . A causal relationship between c-jun expression and the elevated levels of g-GCS and GSH has been shown using an antisense construct directed against c-jun. In these studies, a 20-mer c-jun phosphorothioate ASO was shown to decrease the steady-state levels of c-jun mRNA and protein. As a consequence of this decrease in c-jun levels, the expression of g-GCS mRNA fell, effecting a decline in cellular GSH levels. While we cite this as an example of an alternate strategy to deplete cellular GSH levels, it must be recognized that targeting a transcription factor such as c-jun is likely to have more farreaching consequences. Indeed, a 4-h treatment with 1 mm c-jun antisense reduced c-jun and g-GCS mRNA levels to 7.9 and 5.9% of their starting values, respectively, but reduced GSH content to only 32.7% of the starting level. Given the latter, one must conclude that while targeting c-jun decreases thiol synthesis and levels, the importance of additional effects on unrelated genes on the reversal of drug resistance should not be discounted.
Finally, a recent study found an interesting correlation between Bcl-2 levels and sensitivity to GSH depletion (Vahrmeijer et al., 2000) . By exposing human colon carcinoma cells to increasing concentrations of BSO, the authors were able to isolate a BSO-resistant cell line that was 50 times more resistant to BSO than the parental cell line. The GSH content of both parental and resistant cells was similar, but the resistant cells had a much higher level of Bcl-2 protein. Furthermore, transfection of parental cells with a Bcl-2 vector conferred BSO resistance. These observations indicate that Bcl-2 protein offers resistance against the effects of GSH depletion, and suggest that a strategy that depletes both GSH and Bcl-2 might be synergistic. Synergism might be observed because available evidence suggests that GSH depletion leads to necrotic rather than apoptotic cell death, and a combined strategy might target two independent death pathways (Vahrmeijer et al., 2000; Dedoussis and Andrikopoulos, 2001 ).
Targeting P53
The frequent occurrence of p53 mutations in human cancer has led to numerous investigations evaluating its role as a potential therapeutic target. By restoring wt p53, investigators have sought to either: (1) revert the malignant phenotype or (2) enhance drug sensitivity. These goals are based on available evidence that although not conclusive suggests that: (1) restoration of p53 will have an impact on the malignant phenotype and (2) mutant p53 confers drug resistance. While not a focus of the present review, it can be said that the available data suggest that restoration of wt p53 does not revert the malignant phenotype, but can lead to growth inhibition, although induction of apoptosis would be more desirable.
Since the first introduction of the concept that p53-dependent apoptosis could modulate the cytotoxicity of anticancer agents, our knowledge has expanded, and we now recognize that this original hypothesis is too simplistic (Lowe et al., 1993) . Nevertheless, the question can be asked: are we likely to modulate drug tolerance by introducing wt p53 into a null cell or a cell harboring a mutant p53? Answering this question will ultimately require us to understand the importance of p53 in mediating cell death following chemotherapy. If this is by mediating apoptosis, as is often argued, we must recognize that the mechanism by which p53 mediates apoptosis has become increasingly less clear in recent years as the list of p53-regulated proapoptotic candidates has grown sharply. Included among these are: Bax, CD95/Fas, Noxa, Pidd, PIG3, p53AIP1, PUMA, mtCLIC/CLIC4 and Scotin (Miyashita and Reed, 1995; Owen-Schaub et al., 1995; Polyak et al., 1997; Lin et al., 2000; Oda E et al., 2000; Oda K et al., 2000; Nakano and Vousden, 2001; Yu et al., 2001; Bourdon et al., 2002; Fernandez-Salas et al., 2002) . Importantly, we lack data on whether these various proteins are coregulated, and how they might interact. Despite our limited insight, numerous investigators have shown that levels of p53 above a certain 'threshold' almost invariably lead to apoptosis or to enhanced drug sensitivity (Blagosklonny and el-Deiry, 1998; Waugh et al., 1999; Boulay et al., 2000; Tango et al., 2002) . While this is not conclusive proof that p53 has a central role in mediating drug sensitivity, it suggests at least an ancillary role. Given this, what strategies can we exploit to restore a wt p53 status to cells harboring mutant p53?
The strategies most extensively investigated have utilized one of several viral vectors. Several studies have shown that wt p53 can be introduced using viral vectors, and the available reagents can achieve the 'threshold' levels required to bring about apoptosis. Studies to date have employed conventional vectors and also explored innovative strategies to exploit the p53 status of cancer cells. In the conduct of these trials, important lessons have been learned that are likely to be of benefit in other settings (Rizk et al., 1999; McCormick, 2001 ). The first clinical trials attempting to restore wt p53 function utilized retroviral vectors that constitutively expressed p53 under the control of the actin promoter (Roth et al., 1996) . Following intratumoral injection, expression of p53 and enhanced apoptosis were observed in the injected tumors, and in three of nine patients limited evidence of tumor regression was noted. While the retroviral vector used in these studies proved to be inefficient, this study provided a first 'proof of principle', and became the catalyst for further studies. Subsequent studies have used adenoviral vectors. Advantages of the latter include the ability to infect cells in all phases of the cell cycle, relative ease of growth to high titers and the capacity to accommodate inserts of large size. Its major disadvantages include the frequent occurrence of antibodies in the general population, preferential but not exclusive infection of cells expressing the coxsackie adenovirus receptor (CAR) and au-integrin and its lack of selectivity, so that it infects normal cells, most notably liver, with high efficiency (Bergelson et al., 1998; O'Neal et al., 1998; Fechner et al., 1999; Rochlitz, 2001) . Despite its limitations, Adp53 vectors appear to be well tolerated and expressed in most patients. Clinical trials have shown antitumor activity in patients with squamous cell carcinomas of the head and neck and nonsmall-cell lung cancer (NSCLC), although these results must be considered preliminary pending confirmation in larger phase II and III clinical trials currently underway I (Clayman et al., 1999; Swisher et al., 1999) .
In evaluating these strategies, one must be mindful that p53 participates in regulating the expression of a wide range of genes with diverse functions and that some of these genes may have unanticipated roles in a vector's efficacy. Thus, some of the genes expressed following infection with a p53-expressing adenovirus may modulate a 'bystander effect' by which uninfected cells are damaged as a result of the expression of genes in infected cells. For example, p53 may indirectly regulate angiogenesis by modulating the expression of vascular endothelial growth factor (VEGF) and thrombospondin (Dameron et al., 1994; Bouvet et al., 1998) . p53 also participates in the expression of insulin-like growth factor 1-binding protein (IGF1BP), an antagonist of insulin-like growth factor 1 (IGF-1), a growth factor implicated in tumor cell survival (Buckbinder et al., 1995) .
While the bystander effect enhances efficacy in an indiscriminate manner, attempts have been made to increase the selectivity of viruses so that they replicate preferentially in cancer cells. Most notable among these strategies has been the development of an attenuated adenovirus, most commonly known as ONYX-015 (Bischoff et al., 1996) . Its putative specificity derives from the fact that for adenovirus to replicate effectively once inside the cell, p53 function must be abrogated. Under normal circumstances, the early region protein, E1B 55 K, produced by the adenovirus, mediates functional inactivation of p53. E1B 55 K binds p53 and with the assistance of other viral proteins, targets it for degradation. As ONYX-015 lacks E1B 55 K it cannot degrade p53, and is therefore unable to replicate in cells containing a functional p53; but can replicate in cells lacking normal p53 function. Although originally proposed as a virus that would selectively replicate in cells harboring mutant p53, the specificity of ONYX-015 for cells lacking a wt p53 remains controversial (Dix et al., 2001) . Indeed, its clinical activity may derive from several factors including nonspecific bystander and immune-mediated effects (Khuri et al., 2000; Nemunaitis et al., 2001) . Furthermore, although very preliminary, its activity seems to be enhanced by the coadministration of chemotherapy, supporting the argument that modulation of p53 as a stand-alone strategy is likely to be less effective than a strategy to enhance the efficacy of chemotherapy.
Although the jury is still out on the case of modulating p53 expression using viral vectors, an initial verdict is expected in the not too distant future. This verdict is likely to undergo extensive appeals, but much will have been learned from these early clinical trials that will be of value in other attempts to modulate gene expression in cancer cells (McCormick, 2001) . The success of this strategy will depend on ongoing attempts to enhance the distribution, efficacy, specificity and safety of these reagents since, lacking the ability to direct expression, this strategy might incur significant toxicity. Yet, one must also recognize that chemotherapy is never without side effects, and it would be unreasonable to set the bar higher for an agent targeting p53.
An alternate strategy, the use of small molecules to restore wt function to mutant p53, remains an option, although to date, studies evaluating the ability of these small molecules to modulate drug resistance have not been published (Foster et al., 1999; Bykov et al., 2002) . While the available data are incomplete, it has been suggested that these small molecules restore p53 function by converting the mutant form of p53 into a properly folded active form. Indeed, preliminary evidence indicates that the addition of these small molecules results in transactivation of some p53 target genes. However, a concern is that the available data indicate that the primary effect of these compounds is growth inhibition. The data presented for both PRIMA-1 and CP-31398 emphasize the ability of these compounds to induce the expression of p21. Furthermore, in vivo administration results in histological evidence of 'tumor cell depletion' and absence of vascularization consistent with suppression of tumor growth (PRIMA-1) or growth inhibition that resumes after cessation of treatment (CP-31398). Notably absent is evidence of induction of any of the putative proapoptotic genes transactivated by p53 that it could be argued will be required to enhance drug sensitivity. But putting aside the need to induce proapoptotic genes, the fact is that p21 induction is clearly demonstrated, and that growth inhibition occurs, an outcome that could paradoxically increase drug resistance by limiting the effectiveness of cell cycle-dependent agents. One then must ask if future development of these prototype drugs should strive to identify compounds that preferentially induce proapoptotic genes over or in concert with p21. One must also be concerned that as with all small molecules, drug resistance may emerge, involving not only the target (the most mutable cancer-associated gene identified to date) but also other cellular mechanisms of drug tolerance.
A final approach suggested by some is to transfect or activate some of the p53-inducible proapoptotic proteins (Yu et al., 2001) , in effect, to bypass p53 and exploit p53 transactivation targets directly. In thinking about this, we need to understand that growth suppression should not be equated with the ability to induce apoptosis or cell death. As an example consider PUMA, a gene recently identified by two different groups that appears to encode two BH3 domain-containing proteins that are induced in cells following p53 activation (Nakano and Vousden, 2001; Yu et al., 2001) . Its ability to induce apoptosis has been demonstrated, albeit at PUMA levels that may be higher than those normally found in cells. More impressively, however, the PUMA protein has been shown to suppress the growth of human cancer cells potently. Consequently, the same concern can be raised for this approach that was raised for the use of small molecules. If the principal effect is growth arrest, then it is likely that in some settings this approach will actually be more detrimental than helpful.
Given the unanswered questions about the role of p53 in apoptosis and the ability of p53 to modulate drug resistance, one must ask whether a strategy designed to restore a wt p53 status is likely to be effective. Although time will tell, pursuing such an approach seems very reasonable at this time. In arguing for pursuit of a strategy that restores wt p53 function to cells harboring a mutant or null p53, we would note as an example the evidence in non-Hodgkin's lymphomas (NHL). Although several studies have demonstrated a correlation between p53 status and prognosis in NHL, p53 mutations have been identified as an independent prognostic variable only in aggressive B-cell NHL (Mller et al., 1999) . As the aggressive B-cell NHL is usually most responsive to chemotherapy, modulating p53 might be more successful in patients with these tumors. The goal is to enhance the effectiveness of a therapy that is known to be effective in some cancers by modulating a known prognostic factor. Are there obvious obstacles to a strategy that attempts to transduce a wt p53 into cells harboring a mutant protein? None, that appear unique to p53. Concerns that dominantnegative mutants may inactivate the transduced wt protein are likely unfounded since a majority of acquired mutations appear to lack dominant properties. Thus, strategies attempting to enhance the expression of the wt p53 phenotype in cancer cells deserve further investigation. Although the role of p53 in apoptosis and chemotherapy-induced cytotoxicity are far from settled, a subset of cancers may respond to these strategies.
Overcoming drug resistance mediated by ABC transporters
Conceptually, the simplest mechanism of resistance is one that reduces intracellular drug accumulation. A reduction in intracellular drug levels leads to a reduction in the amount of drug that can reach a target, and in turn a reduction in cytotoxicity. From the point of view of the cell, it might be argued that this is the most efficient and most reliable manner to achieve resistance; a view supported by the frequency with which drug transporters have been identified as mechanisms of cellular resistance.
In the 30 years since the first description of a resistant cell line with reduced drug accumulation, much has been learned, but even more remains to be discovered (Dano, 1973) . During this time, hundreds of laboratories have reported in vitro selections with natural product anticancer drugs such as paclitaxel, doxorubicin or vinblastine. In a majority of these models, development of resistance was accompanied by cross-resistance to structurally different compounds, and was mediated by the ABC transporter, Pgp, the product of the MDR1 (or ABC B1) gene (Juliano and Ling, 1976; Ueda et al., 1987) . Reports in the early 1980s demonstrating reversal of resistance in vitro by verapamil, raised hopes that drug resistance could be reversed by inhibiting drug efflux and focused resources and efforts in this endeavor (Tsuruo et al., 1983; Germann et al., 1997) .
The first strategy utilized to inhibit Pgp function relied on the identification of nonchemotherapeutic Strategies for reversing drug resistance T Fojo and S Bates agents as competitors. It was reasoned that since these compounds were not cytotoxic, high levels could be administered and maintained without encountering toxicity. By competing for efflux by Pgp these compounds would act as inhibitors. As Pgp is a broadspectrum efflux pump that binds a wide variety of hydrophobic compounds, it was relatively easy to identify potent inhibitors. However, attempts to characterize a pharmacophore so as to rationally develop better inhibitors have met with only modest success (Ford and Hait, 1990) . Numerous clinical trials were conducted encouraged by studies demonstrating frequent expression of Pgp in various tumors, and supported by reports documenting the adverse prognostic impact of Pgp expression. Agents evaluated since the early 1980s when these studies began include: verapamil, the phenothiazines, quinidine, quinacrine, quinine, amiodarone, several neuroleptics, tamoxifen, progesterone, cyclosporin A, dexverapamil, dexniguldipine, GF120918, PSC-833 (valspodar), VX-710 (biricodar), XR9576 (tariquidar) and others (Ford and Hait, 1990; Trump et al., 1992; Fisher et al., 1996) . Trials attempting to modulate drug resistance have undergone a gradual evolution from early trials using agents already approved by the FDA for other indications, to subsequent studies with more potent agents developed as Pgp inhibitors, to ongoing trials using highly potent and specific inhibitors.
Guided by data demonstrating the expression of Pgp in acute myelocytic leukemia (AML), a large number of trials have been conducted in patients with AML. Initial studies compared their results to those of historical controls, and demonstrated an improved response in patients with relapsed or refractory AML, older patients with AML and patients with myelodysplastic syndrome who developed AML (List et al., 1993; Kornblau et al., 1997; Advani et al., 1999; Lee et al., 1999) . In one study, the Pgp inhibitor quinine increased the complete response rate and disease-free survival in patients with Pgp-positive cells, but not in those whose cells were Pgpnegative (Solary et al., 1996) . In addition, a large prospective randomized study using cyclosporin A in patients with AML showed an improved relapse-free and overall survival for patients receiving cyclosporin (List et al., 2001) . Although these studies suggested that inhibition of Pgp could benefit patients with AML, this conclusion is disputed by other randomized trails. Similar observations have been reported in other Pgpexpressing malignancies. In one trial, patients with NSCLC were randomized to receive vindesine (a Pgp substrate) and ifosfamide without or with verapamil (Millward et al., 1993) . In all, 41% of those receiving verapamil had tumor shrinkage compared with 18% of those receiving chemotherapy alone. In addition, the median survival from the start of treatment was significantly better in the verapamil arm. Again, while these studies suggest a benefit from blocking Pgp, other studies do not agree. Excellent reviews that catalog completed trials are available (Ferry et al., 1996; Fisher et al., 1996; Fisher and Sikic, 1995; Bradshaw and Arceci, 1998) .
For most inhibitors, the development strategy adopted consisted of determining the maximum tolerated dose (MTD) and administering this in combination with the anticancer agent. It was felt that high concentrations were needed because preclinical evidence suggested that serum protein binding would reduce the inhibitor's effectiveness (Lehnert et al., 1996) . As a result of this strategy some agents, such as PSC-833, were administered at doses exceeding that needed to inhibit Pgp fully, as evidenced by use of surrogate markers . Although the need for these high doses has never been clearly demonstrated, they contributed to the problem that sealed their demise: a variable pharmacokinetic (PK) interaction necessitating reductions in the dose of the anticancer agents (Fedeli et al., 1989; Wilson et al., 1995; Rowinsky et al., 1998) . The mechanism responsible for these reductions involved at least in part inhibition of cytochrome P450, with a resultant interference in the hepatobiliary handling of the chemotherapeutic agents (Relling, 1996; Song et al., 1998) . While PK interactions appear to have been most pronounced with PSC-833 and cyclosporin A (Lum et al., 1992; Bartlett et al., 1994) , similar PK interactions were reported with other Pgp inhibitors including verapamil, dexverapamil, nifedipine and VX 710 (Kerr et al., 1986; Fedeli et al., 1989; Wilson et al., 1995; Rowinsky et al., 1998) . By both requiring unacceptable reductions in the dose of the anticancer agents, and making it nearly impossible to interpret the results of the clinical trials, this problem more than any other has interfered with the development of Pgp inhibitors.
Thus, after nearly 15 years, there is still no definitive answer to the question: can a Pgp inhibitor effectively reverse drug resistance in humans? In retrospect it is clear that early trials were premature and that the agents utilized were at best weak inhibitors in vivo. Subsequent trials highlighted the problem of PK interactions. The current goal is to develop a compound with much less and more predictable PK effects; that is also more potent than previous inhibitors. However, it must be emphasized that it is unlikely that a Pgp inhibitor devoid of all PK interactions will be found. One can infer from the mdr1a/mdr1b knockout mouse data that complete inhibition of Pgp will likely result in some PK perturbation. Compounds in development that appear to satisfy these requirements include: XR9576 (Tariquidar), R101933, LY335979, OC144-093 and GF120918 (Dantzig et al., 1999; Sparreboom et al., 1999; Newman et al., 2000; Stewart et al., 2000; van Zuylen et al., 2000; Mistry et al., 2001) .
While the jury is still out on the efficacy of small molecule inhibitors, other strategies have been proposed to overcome resistance mediated by Pgp. Included among these are the use of hammerhead ribozymes against the MDR-1 gene and MDR-1-targeted ASOs (Liu et al., 1996; Dassow et al., 2000; Huesker et al., 2002; Nagata et al., 2002) . Hammerhead ribozymes are oligonucleotides that possess enzymatic endoribonucleolytic cleavage activity (Irie et al., 1997) . Numerous studies have demonstrated that hammerhead ribozymes can cleave specific mRNA molecules resulting in reduced expression of target genes, including mRNAs encoding genes conferring drug resistance (Holm et al., 1994; Kobayashi et al., 1994) . Hammerhead ribozymes can be designed to cleave a given mRNA at a specific position in trans provided the target mRNA contains an NUX motif, where N is any nucleotide and X is A, C or U. Like ASOs, hammerhead ribozymes achieve their effect by reducing mRNA levels. Both hammerhead ribozymes and ASO are synthetic, susceptible to degradation and can be recycled so that they can affect more than one target mRNA. As noted above, although ASOs lack intrinsic cleavage activity they recruit the endonuclease, RNAse H, which cleaves and thus destroys the target mRNA releasing the ASO intact to hybridize to another mRNA. As ASOs must recruit RNAse H, a putative advantage of hammerhead ribozymes is their intrinsic endoribonucleolytic cleavage activity. A second potential advantage is the ability to target specific cells. Most in vitro studies utilize plasmidbased ribozyme constructs that require the isolation of single cells, and further selection in an agent such as G418. While these studies provide proof of principle, they have no potential clinical value. However, several studies have demonstrated the feasibility of using adenoviral-based constructs. Furthermore, these studies have shown that using promoters with 'tumor specificity' such as AFP and CEA, expression can be limited to cells expressing these proteins (Gao et al., 1999; Huesker et al., 2002) . Although the experimental results indicate that these strategies are effective in vitro, their clinical utility will be limited if a potent small molecule inhibitor of Pgp is identified.
The recognition that not all multidrug-resistant cells with reduced drug accumulation express Pgp prompted a search for additional drug transporters. The first of these to be identified, the multidrug resistance-associated protein 1 (MRP1 or ABCC1) is similar to Pgp in several respects (Cole et al., 1992) . However, unlike Pgp, MRP1 recognizes neutral and anionic hydrophobic natural products, and transports metabolic conjugates of these drugs (Muller et al., 1994; Jedlitschky et al., 1996; Hipfner et al., 1999) . In some cases such as for vincristine, MRP1 appears to cotransport GSH without conjugation (Loe et al., 1998) . The discovery of MRP1 led to a search for homologs in the human genome, with the discovery of eight other members of the ABCC subfamily of transporters, of which six have been studied in some detail (Borst et al., 2000a) . The importance of these transporters in conferring clinical resistance remains to be determined.
While clinical studies have not been conducted with MRP inhibitors, several have been identified and characterized in vitro (Avendano and Menendez, 2002) . That they appear not to be as potent as Pgp inhibitors most likely reflects a lack of a concerted effort to develop these agents for clinical use until the outcome of Pgp inhibition is clarified. As with Pgp, other strategies have been utilized to inhibit the function of MRP1. Among these the most effective appears to be a ribozyme strategy similar to that used for Pgp (Stewart et al., 1996) .
In addition to the MRP family members, recent studies have shown that selection for resistance to mitoxantrone results in multidrug-resistant cells that express a more distant member of the ABC transporter family known as ABCG2 . Selection for resistance to anthracyclines in the presence of a Pgp inhibitor also results in the expression of the same transporter (Doyle et al., 1998) . This transporter differs somewhat from the MDR and MRP families in that it consists of one ATP-binding domain and six TM segments and is presumed to function as a homodimer. It is presumed that this homodimer is responsible for the observed drug efflux, and like with Pgp and MRP1, one goal has been to develop ways to inhibit drug efflux. Again, small molecule inhibitors have been pursued aggressively, with the identification of several putative inhibitors including Fumitremorgin-c (FTC), a metabolite of Aspergillus fumigatus and GF120918 (de Bruin et al., 1999; Maliepaard et al., 2001; Rabindran et al., 2000) . The latter, a known Pgp inhibitor, also inhibits ABCG2 at concentrations as low as 100 nm. In addition, as for Pgp and MRP1, a hammerhead ribozyme directed against ABCG2 has been shown to reverse drug resistance (Kowalski et al., 2002) .
Finally, other members of the ABC family have been reported to confer drug resistance, albeit not as efficiently as those discussed above. Included among these are: (1) the bile salt transporter or BSEP, first reported as the 'sister of Pgp' (SPGP), which is expressed at high levels in liver cells, and confers resistance to paclitaxel (Childs et al., 1998) . (2) MDR2, a phosphatidyl choline flippase closely related to Pgp that transports phospholipids into the bile and can transport paclitaxel and vinblastine (Smit et al., 1993; Borst et al., 2000b) . (3) ABCA2, a transporter expressed intracellularly in endosomal/lysosomal vesicles where it may participate in steroid transport, has been reported to confer resistance to estramustine, a nitrogen mustard derivative of estradiol (Laing et al., 1998; Vulevic et al., 2001) .
Conclusions
Despite more than 20 years of effort, one must concede that modulation of drug resistance has not yet been proven to be an effective clinical tool. But one must also recognize the myriad of difficult obstacles encountered on this journey. Often, as these have been overcome, new obstacles have emerged, and these in turn have had to be conquered. Along the way, we have learned an enormous amount about drug resistance, and have seen the development of a field seeking to exploit this knowledge to protect normal cells from the toxic effects of cancer drugs (Sorrentino, 2002) . We are now poised to put some of these strategies to the ultimate test. Should we succeed, the road will have been paved for future developments based on these pioneering basic and clinical studies.
